NEW YORK, Oct. 23-The German synthetic antibody firm MorphoSys said today that it had terminated merger talks with British Biotech, a publicly owned drug development company.
MorphoSys said that it did not expect to realize any equity-based transactions or partnerships this year, and reduced its year-end cash position guidance to roughly € 15 million. The company held cash and cash equivalents of € 568,987 as of June 30, 2002.